Last updated on April 2019

Evaluation of EYS606 in Patients With Non-infectious Posterior Intermediate or Panuveitis

Brief description of study

Primary objective: safety and tolerability

Secondary objectives: additional indicators of long term safety and indicators of clinical activity

Exploratory objectives: to characterize EYS606 biodistribution, immunogenicity and biomarkers

Detailed Study Description

The maximum study duration per patient is 27 Weeks (including an up to 3 week screening period + 24 weeks follow-up after treatment).

The study is conducted in 2 parts. Part 1 is a dose escalation phase which will investigate 3 pEYS606 doses levels (lower, intermediate and higher dose) over 3 cohorts. Part 2, the extension phase will confirm to safety of the maximum tolerated dose from Part 1 and allow a preliminary assessment of efficacy.

Clinical Study Identifier: NCT03308045

Find a site near you

Start Over